TAILORx Trial Shows Women at Low Risk for Breast Cancer Recurrence May Forgo Chemotherapy
A summary of results from the Trial Assigning Individualized Options for Treatment, or TAILORx, finds that women with early-stage hormone receptor-positive breast cancer have a low risk of recurrence based on a test for the expression of 21 genes.
Media Type: Html
- SourceUrl: https://www.cancer.gov/publishedcontent/syndication/1004820.htm
- Syndication ID: 19826
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Monday, March 23, 2020 at 07:16 PM
- Date Syndication Updated: Monday, September 21, 2020 at 06:17 AM
Tags
General:
lymphedema
breast cancer
TAILORx
oncotype dx
hormone receptor-positive
recurrence
hormone therapy
Embed Code Snippet
To get the embed code snippet please Login.
